Rosetta Genomics' H1 2011 Revenues Fall 39 Percent | GenomeWeb

By a GenomeWeb staff reporter



NEW YORK (GenomeWeb News) – Rosetta Genomics' first-half 2011 revenues fell 39 percent year over year, the Israeli microRNA-based molecular diagnostics company reported after the close of the market on Friday.

In a document filed with the US Securities and Exchange Commission, it said that revenues for the first six months of the year came in at $59,000, down from $97,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.